...
首页> 外文期刊>Biological & pharmaceutical bulletin >Formulation, preparation and evaluation of an intravenous emulsion containing Brucea javanica oil and Coix Seed oil for anti-tumor application.
【24h】

Formulation, preparation and evaluation of an intravenous emulsion containing Brucea javanica oil and Coix Seed oil for anti-tumor application.

机译:含有布鲁斯爪哇油和Co仁油的静脉内乳液的配制,制备和评估,可用于抗肿瘤。

获取原文
获取原文并翻译 | 示例
           

摘要

The purpose of this study was to prepare and evaluate the intravenous emulsion (BCOE) containing Brucea javanica oil (BJO) and Coix seed oil (CSO), which is used in anti-tumor treatment. The formulation and preparation of BCOE were systematically investigated. High-pressure homogenization, particle size distribution, zeta-potential and HPLC were carried out. The pharmacokinetics of the main component, oleic acid, and anti-tumor activity studies about the tumor growth inhibitory ratios (TGIR) and the mortality experiments were also employed to evaluate BCOE in vivo compared with BJO emulsion (BJOE) and CSO emulsion (CSOE) using S180 sarcoma-bearing mice. The final BCOE formulation was 10% (w/v) oils with BJO and CSO 3 : 1, 0.6% (w/v) Lipid E 80, 0.3% (w/v) Pluronic F-68 (F-68), 0.1% (w/v) sodium oleate and 2.5% (w/v) glycerin in water. The preparation conditions involved 70 degrees C for preparing the crude emulsion, 6 cycles for high-pressure homogenization at 500 bar, pH value was adjusted to 8.5 after high-pressure homogenization and 115 degrees C for 30 min in a rotating water bath for sterilization. The pharmacokinetics parameters showed the combination of BJO and CSO may not influence the elimination of BCOE and have no significant difference between BCOE and BJOE or CSOE. The data of TGIR and mortality indicated that BCOE could increase the anti-tumor activity of CSOE and reduced the toxicity of BJOE. The mortality study (BCOE 0, BJOE 63.3%, CSOE 13.3%) showed that BCOE greatly reduced the toxicity of BJOE and CSOE. Therefore, the development and application of BCOE will make an important contribution to anti-tumor therapy.
机译:这项研究的目的是准备和评估静脉内乳液(BCOE),该乳液包含爪哇布鲁斯油(BJO)和Co仁籽油(CSO),用于抗肿瘤治疗。对BCOE的配方和制备进行了系统的研究。进行高压均质化,粒度分布,ζ电位和HPLC。与BJO乳剂(BJOE)和CSO乳剂(CSOE)相比,还采用了主要成分,油酸的药代动力学以及关于肿瘤生长抑制率(TGIR)的抗肿瘤活性和死亡率实验来评估体内BCOE。使用S180肉瘤小鼠。最终的BCOE配方是10%(w / v)的BJO和CSO 3油:1,0.6%(w / v)脂质E 80,0.3%(w / v)Pluronic F-68(F-68),0.1 %(w / v)油酸钠和2.5%(w / v)甘油在水中。制备条件包括70℃用于制备粗乳液,6个循环用于在500bar下高压均化,高压均化后将pH值调节至8.5,并在旋转水浴中在115℃下调节30分钟以进行灭菌。药代动力学参数表明BJO和CSO的结合可能不会影响BCOE的消除,并且BCOE与BJOE或CSOE之间没有显着差异。 TGIR和死亡率数据表明,BCOE可以增强CSOE的抗肿瘤活性,并降低BJOE的毒性。死亡率研究(BCOE 0,BJOE 63.3%,CSOE 13.3%)表明,BCOE大大降低了BJOE和CSOE的毒性。因此,BCOE的开发和应用将为抗肿瘤治疗做出重要贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号